# Intelligent Fingerprinting

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/intelligent-fingerprinting

- Industry: Medical Devices & Equipment
- Headquarters: Cambridge, UK
- Website: www.intelligentfingerprinting.com
- Total disclosed funding: $0.3M
- Latest round: Seed (Jul 22, 2010)
- Investors on record: 1

## About

Intelligent Fingerprinting Ltd. offers innovative fingerprint-based drug testing solutions aimed at enhancing workplace safety through rapid and non-invasive screening methods.Founded in 2007 in Cambridge, UK, Intelligent Fingerprinting Ltd. specializes in fingerprint drug testing technology. The company has undergone strategic pivots to focus on portable drug screening methods. In October 2022, GBS Inc. acquired the company, with the financial terms undisclosed. The founder's details are not specified, and the company has completed 13 deals to date, with a total amount raised of GBP 2.310 mn, culminating in a current valuation of GBP 3.754 mn.Intelligent Fingerprinting specializes in innovative fingerprint drug testing solutions designed for workplace safety. The company's core offering is a compact and portable drug screening system that utilizes fingertip sweat for analysis, allowing for rapid and non-invasive testing with a detection window of 16 to 24 hours. This technology is aimed primarily at identifying potential impairment rather than past drug use, making it suitable for various sectors including construction, manufacturing, transport and logistics, and mining. Customers and end-users range from safety officers and human resources managers to operations directors within organizations that prioritize employee safety and compliance with industry regulations. Intelligent Fingerprinting's products are primarily marketed in the United Kingdom, with growing interest in international markets due to increasing global demands for efficient and dignified drug testing solutions.Intelligent Fingerprinting generates revenue through direct business transactions with clients, focusing on B2B models. Their sales structure includes partnerships with various industries to provide drug testing services, allowing companies to implement the Intelligent Fingerprinting system in-house. The company’s flagship product facilitates batch testing, enabling rapid analysis of drug screening results, which appeals to organizations aiming to enhance workplace safety while minimizing testing costs. While specific pricing plans are not disclosed, the model emphasizes cost savings compared to traditional urine-based testing methods, positioning the Intelligent Fingerprinting system as a financially viable alternative for many businesses. The company's revenue streams are bolstered by the increasing demand for reliable drug testing solutions across multiple sectors, leading to a robust client base.With the acquisition by GBS Inc. in October 2022, Intelligent Fingerprinting is expected to leverage new investment opportunities to expand its product line and market reach. The company aims to introduce new products that enhance drug testing capabilities and plans to enter international markets, focusing on regions with increasing regulatory scrutiny on workplace drug testing practices. The recent funding of GBP 2.310 mn will be utilized to support these initiatives, promoting further development of their technology and expanding their global presence.

## Funding rounds

- Seed, Jul 22, 2010, $0.3M — Iceni Capital

## Investors

- Iceni Capital (https://capitalatlas.ai/funds/iceni-capital) — Seed